ENOXAPARIN

Course overview

ENOXAPARIN IS LOW MOLECULAR WEIGHT HEPARIN (LMWH) AND WAS FIRST APPROVED FOR MEDICAL USE IN 1993 AND IS DERIVED FROM HEPARIN. IT HAS APPROVAL FOR THE FOLLOWING CLINICAL CONDITIONS - ACUTE CORONARY SYNDROMES, DEEP VENOUS THROMBOSIS (DVT) TREATMENT AND PROPHYLAXIS, TREATMENT FOR PULMONARY EMBOLISM (PE), VENOUS THROMBOEMBOLISM (VTE) TREATMENT AND PROPHYLAXIS IN A VARIETY OF SCENARIOS, PERCUTANEOUS CORONARY INTERVENTION (PCI), AND PERIPROCEDURAL ANTICOAGULATION, AMONG OTHERS. THIS ACTIVITY WILL HIGHLIGHT THE MECHANISM OF ACTION, ADVERSE EVENT PROFILE, PHARMACOLOGY, MONITORING, AND RELEVANT INTERACTIONS OF ENOXAPARIN, PERTINENT FOR MEMBERS OF THE INTERPROFESSIONAL TEAM IN THE TREATMENT OF PATIENTS WITH CONDITIONS WHERE THIS AGENT IS INDICATED.